4'Cl-CUMYL-PINACA
Legal status | |
---|---|
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H26ClN3O |
Molar mass | 383.92 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
4'Cl-CUMYL-PINACA (also known as SGT-157) is an indazole-3-carboxamide based synthetic cannabinoid compound, first disclosed in a 2014 patent.[1] It has been sold as a designer drug, first reported in 2020 alongside two similar compounds 4'F-CUMYL-5F-PICA (SGT-64) and 4'F-CUMYL-5F-PINACA (SGT-65),[2] and the metabolism of these compounds has been studied to assist with their identification in forensic casework.[3]
See also
References
- ↑ WO 2014167530, Bowden MJ, Williamson JP, "Cannabinoid compounds", published 16 October 2014.
- ↑ Zangani C, Schifano F, Napoletano F, Arillotta D, Gilgar L, Guirguis A, et al. (2020). "The e-Psychonauts' 'Spiced' World; Assessment of the Synthetic Cannabinoids' Information Available Online". Current Neuropharmacology. 18 (10): 966–1051. doi:10.2174/1570159X18666200302125146. PMC 7709145. PMID 32116194.
- ↑ Stalberga D, Ingvarsson S, Bessa G, Maas L, Vikingsson S, Persson M, et al. (December 2022). "Metabolism studies of 4'Cl-CUMYL-PINACA, 4'F-CUMYL-5F-PINACA and 4'F-CUMYL-5F-PICA using human hepatocytes and LC-QTOF-MS analysis" (PDF). Basic & Clinical Pharmacology & Toxicology. 132 (3): 263–280. doi:10.1111/bcpt.13829. PMID 36544361. S2CID 255039508.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.